` PANG (Pangaea Oncology SA) vs DAX Index Comparison - Alpha Spread

PANG
vs
D
DAX Index

Over the past 12 months, PANG has underperformed DAX Index, delivering a return of -5% compared to the DAX Index's +19% growth.

Stocks Performance
PANG vs DAX Index

Loading
PANG
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PANG vs DAX Index

Performance Gap Between PANG and GDAXI
HIDDEN
Show

Performance By Year
PANG vs DAX Index

Loading
PANG
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Pangaea Oncology SA vs Peers

DAX Index
PANG
0KHE
TMO
DHR
LONN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Pangaea Oncology SA
Glance View

Pangaea Oncology SA provides molecular diagnostics and research development services in the field of personalized cancer treatment. The company is headquartered in Barcelona, Barcelona and currently employs 50 full-time employees. The company went IPO on 2016-12-29. The firm focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.

PANG Intrinsic Value
HIDDEN
Show
Back to Top